Zydus receives USFDA’s final approval for Valsartan Tablets

The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India

Thyrocare Technologies posts Q1 FY25 consolidated profit at Rs. 24.17 Cr

Thyrocare Technologies has reported total income of Rs. 160.53 crores during the period ended June 30, 2024

Torrent Pharmaceuticals posts Q1 FY25 consolidated PAT at Rs. 457 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2,883 crores during the period ended June 30, 2024

Alembic receives USFDA’s final approval for Fluphenazine Hydrochloride Tablets

Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr

Reported profit after tax declined 19% year-on-year to Rs 76 crores

USFDA successfully inspects Carbogen Amcis’s manufacturing sites in Neuland and Aarau

The inspections concluded with no Form 483 observations or significant critical findings

Poly Medicure posts Q1 FY25 consolidated PAT at Rs. 74.03 Cr

Poly Medicure has reported total income of Rs. 401.69 crores during the period ended June 30, 2024

Solara Active Pharma Sciences reports Q1 FY25 consolidated loss at Rs. 13.46 Cr

Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024

Zydus receives approval from COFEPRIS of Mexico to market ‘Bhava’ to treat various cancers

Caplin Steriles gets USFDA approval for Ephedrine Sulfate injection USP

Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension